Telor Ophthalmic Pharmaceuticals Inc. (NASDAQ:TELR)announced Tuesday that the Medicines Control Agency of theUnited Kingdom's Department of Health has cleared thecompany's Clinical Trial Exemption application, allowing Telorof Woburn, Mass., to begin Phase III trials for Xarano in theUnited Kingdom.

Telor is developing Xarano for controlling acute increases inintraocular pressure after patients have cataract surgery.

Xarano, a formulation of ethacrynic acid, is to be administeredat the time of cataract surgery by the ophthalmic surgeon toprevent or reduce transient post-operative rises in intraocularpressure (IOP spike) by promoting the outflow of fluid fromthe eye.

The trial in the United Kingdom is part of Telor's pivotal PhaseIII clinical evaluation program for Xarano that includesapproximately 20 clinical centers at sites in the U.S., Canada,Europe and Israel. Telor began multicenter Phase III studies inthe U.S. in April.

(c) 1997 American Health Consultants. All rights reserved.